Antioxidant drugs constitute a new pharmacological group of drugs having a diverse spectrum of biological activity. Their high efficiency has been established in medical practice. Competitive synthesis technologies are being developed for the 2,6-diisobornil-4-methylphenol («Dibornol») and for making drugs based thereon, which have a combined effect on haemorheology, vascular platelet haemostasis; these drugs exhibit antioxidant, neuroprotective and retinoprotective activity for the prevention and treatment of thrombophilic states, increased blood viscosity syndrome, and endothelial dysfunction caused by cardiovascular diseases and diabetes.

FIELD OF APPLICATION : Medicine; Neurology.

MAJOR ADVANTAGES

Dibornol is a drug that shows antioxidant, haemorheological, antithrombotic, neuroprotective, and retinoprotective activity; it enhances the cerebral blood flow, which is vital for the effective treatment of chronic cerebral circulation disturbances. the drug exhibits hypotoxicity. The technologies developed and the Dibornol substance and drug product thus obtained are competitive in the market and can be

offered as an efficient remedy for treating socially significant cardiovascular diseases and diabetes. The Pharmacology Research Institute at Tomsk Scientific Center, Siberian Branch of the Russian Academy of Sciences, has carried out relevant  pharmacology studies.